Long-term Safety Trial with NVDX3
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNovadip Biosciences
About this trial
An study evaluating the long-term safety of all patients previously treated with NVDX3.
Eligibility criteria
Qualifiers
Patient being implanted with NVDX3.
Previously participated to one of the NVDX3 core clinical trials.
Patient accepts to comply to a yearly follow-up safety visit for 10 additional years
Patient has understood and accepted to participate in the long-term follow-up study by signing the informed consent.
Disqualifiers
None
Trial design
Treatments tested in this trial
- NVDX3
Treatment groups
15 Participants
are divided into 1 treatment groupLocations
1Centre Hospitalier de Luxembourg1210, Luxembourg Luxembourg
Sponsors and collaborators
Novadip Biosciences
Lead sponsor
PrimeVigilance
Collaborator
Data Investigation Company Europe (DICE)
Collaborator
Source ClinicalTrials.gov